Prostate Cancer

Prostate Cancer

Prostate Cancer and PARP Inhibitors: Progress and Challenges

In solid tumors, the first demonstration of an improvement in overall survival is provided by olaparib in patients with mCRPC harboring homologous recombination repair deficiencies.

Journal of Hematology & Oncology
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer

This study investigates whether grouping genomic alterations with other events within the same cellular pathways would offer increased precision for biomarker discovery. 


Distinct DNA Methylation Patterns Associated With Treatment Resistance in Metastatic Castration Resistant Prostate Cancer

Investigating the dynamics of the methylation changes going from the castration sensitive to the tNEPC state would provide insights into novel mechanisms of resistance. 

Scientific Reports
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

Study investigators demonstrate that in hormonal sensitive human prostate cancer cells the combination therapy of Abiraterone plus Enzalutamide reduced cell growth and survival. 

LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, PSMA-targeted radionuclide therapy reduces the risk of disease progression or death by 37% vs cabazitaxel in men with mCRPC...

The ASCO Post
Can Treatment for Prostate Cancer Affect Smell and Taste?

One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al. 

The ASCO Post
Radiotherapy of Oligometastatic Prostate Cancer

Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy.

Radiation Oncology
Cell-Free DNA Concentration and Fragment Size as a Biomarker for Prostate Cancer

This study investigates whether differences in cfDNA concentration and cfDNA fragment size could improve the sensitivity for detecting more advanced and aggressive prostate cancer.

Scientific Reports
Effect of Prior Cancer on Survival Outcomes for Patients With Advanced Prostate Cancer

Whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer remains largely unknown.

BMC Urology
Identification of Lipidomic Profiles Associated With Drug-Resistant Prostate Cancer Cells

The association of circulating lipids with clinical outcomes of drug-resistant castration-resistant prostate cancer is not fully understood.

Lipids in Health and Disease
Liquid vs Tissue Biopsy in Prostate Cancer: Why Not Both?

The genomic landscape of circulating tumor DNA was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant prostate cancer. 

The Expression of YWHAZ and NDRG1 Predicts Aggressive Outcome in Human Prostate Cancer

This study aims to identify molecular biomarkers that could improve risk prediction in prostate cancer.

Establishment and Validation of a Novel Predictive Model to Quantify the Risk of Bone Metastasis in Patients With Prostate Cancer

This study aims to construct and validate a nomogram to quantify bone metastasis risk in patients with prostate cancer. 

Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer

This study seeks to answer the question surrounding the most effective systemic treatments for metastatic castration-sensitive prostate cancer.

JAMA Oncology
18F-Guided PET Radiotracing Boosts Survival After Prostate Cancer Relapse

Adding the 18F-fluciclovine PET radiotracer to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, results from a Phase III study show.

Oncology Times - Latest Articles

source list reference